Seres Therapeutics logo
Seres Therapeutics
MCRB | NASDAQ
Chart Builder DCF Calculator
$1.41
+$0.01 (+0.71%)
At close: Nov 16, 2026, 4:00 PM ET
$1.53
+$0.12 (+8.18%)
After-hours: Nov 16, 2026, 6:35 PM ET

Seres Therapeutics Company Profile

Company profile explained

Company Profile

Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI). The company's pipeline further encompasses SER-155, a synthetically cultured bacterial formulation currently undergoing Phase Ib evaluation. This candidate aims to mitigate the risk of gastrointestinal and bloodstream infections, alongside graft-versus-host disease, in vulnerable patients undergoing allogeneic hematopoietic stem cell or solid organ transplantation. Additionally, Seres Therapeutics is advancing SER-287 and SER-301, both in Phase Ib for ulcerative colitis, as well as SER-401, which targets metastatic melanoma, and SER-262, also directed at Clostridioides difficile infection. Seres maintains strategic alliances through licensing and collaboration agreements with entities such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center. Established in 2010, the company previously operated as Seres Health, Inc. before adopting its current name in May 2015, and it maintains its principal offices in Cambridge, Massachusetts.

Key Executives

Name Position
Richard N. Kender Interim CEO & Executive Chair
Chris McChalicher Executive Vice President & Chief Technology Officer
Thomas J. DesRosier Executive VP, Chief Legal Officer & Secretary
Ann Kurowski Senior Vice President of Regulatory Affairs
Dennis Walling Senior Vice President of Clinical Development & Head of Clinical Research
Kelly Brady Executive VP & COO
Marella Thorell Executive VP, CFO & Treasurer
Matthew R. Henn President & Chief Scientific Officer

Latest SEC Filings

Date Type Title
Oct 26, 2026 8-K Current Report
Aug 21, 2026 EFFECT Filing
Aug 18, 2026 4 Filing
Aug 18, 2026 4 Filing
Aug 18, 2026 4 Filing
Aug 18, 2026 4 Filing
Aug 13, 2026 S-3 Filing
Aug 05, 2026 10-Q Quarterly Report
Aug 05, 2026 8-K Current Report
Aug 04, 2026 8-K Current Report
View All SEC Filings ➞
Seres Therapeutics
Seres Therapeutics logo
Country United States
IPO Date Jun 26, 2015
Industry Biotechnology
Sector Healthcare
Employees 66
CEO Richard N. Kender

Contact Details

101 Cambridgepark Drive Cambridge, Massachusetts 02140 United States

Stock Details

Ticker Symbol MCRB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001609809
CUSIP Number 81750R201
ISIN Number US81750R2013
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.